-- Simcere Pharmaceutical (HKG:2096) posted profit attributable to equity shareholders of 1.34 billion yuan for 2025, up 86% from 722 million yuan a year earlier, according to a Tuesday Hong Kong bourse filing.
Shares of the pharmaceutical firm were down 1% in recent trade.
Earnings per share came in at 0.54 yuan from 0.29 yuan a year earlier.
Revenue rose 16.5% to 7.73 billion yuan from 6.64 billion yuan in 2024.